(This commentary was not written by CRD, but by the authors of the DH Register.)
For an annual screen: 1) Survival is unsatisfactorily truncated at 7 years, but extrapolation is uncertain (recurrence, natural history). 2) QOL: treated women are dealt with in an illustrative manner; asymptomatic womenwith false positive results or negative biopsy are omitted. 3) The costing model is extensive, however, complications of diagnosis and treatment are not quantified. For three yearly screen: 4) Survival is extrapolated from 7 to 15 years but extrapolation is uncertain (recurrence, natural history). 5) QOL: asymptomatic women with false positive results or negative biopsy can not be included in the analysis using LYs. 6) The improvement in survival, in the Edinburgh trial, was not statistically significant at seven years. 7) The hypothesis was driven. 8) There were health omissions.